Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–85 of 85 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gammaplex 10 Clear all

Conditions: Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions: Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG); Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mild Cognitive Impairment
Interventions: NewGam 10% IVIG, Placebo; Drug · Other
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Dermatomyositis
Interventions: Octagam 10%, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Huntington Beach, California • Los Angeles, California • Orange, California + 14 more

Conditions: Covid-19
Interventions: Octagam 10%, Saline Solution; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more

Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions: Immune Globulin Intravenous (Human), 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more

Conditions: Mucocutaneous Lymph Node Syndrome
Interventions: IVIG, Infliximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Biliary Atresia
Interventions: Intravenous immunoglobulin (IVIG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Days to 120 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Heart Transplantation
Interventions: Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Pemphigus Vulgaris
Interventions: intravenous immunoglobulin, cyclophosphamide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions: IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose); Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Search by objective public record fields.

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)